CORTINOVIS, DIEGO LUIGI
CORTINOVIS, DIEGO LUIGI
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)
2025 Lee, S; Schulz, C; Baird, A; Prabhash, K; Kowalski, D; Szczesna, A; Han, B; Rittmeyer, A; Talbot, T; Vicente, D; Califano, R; Cortinovis, D; Le, A; Huang, D; Liu, G; Cappuzzo, F; Reyes Contreras, J; Reck, M; Palmero, R; Perez Mak, M; Hu, Y; Morris, S; Kaul, M; Corey-Lisle, P; Gitlitz, B; Peters, S
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)
2025 Facchinetti, F; Camerini, A; Bennati, C; Bordi, P; Carlo, E; Mazzoni, F; Metro, G; Bertolini, F; Longo, L; Ricciardi, S; Pilotto, S; Giardina, D; Passiglia, F; Scotti, V; Piacentini, P; Frega, S; Calabrò, L; Guida, A; Grosso, M; Longobardi, J; Merlini, A; Cosso, F; Leonetti, A; Gariazzo, E; Guaitoli, G; Belluomini, L; Bearz, A; Tognetto, M; Bria, E; Cortinovis, D; Novello, S; Maio, M; Tiseo, M
Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database
2025 Reale, M; Scattolin, D; Vitale, A; Passiglia, F; Grisanti, S; Macerelli, M; Galetta, D; Sini, C; Minuti, G; Citarella, F; Roca, E; Agustoni, F; Dodi, A; Cortinovis, D; Belluomini, L; Ricciardi, S; Veccia, A; Pizzutilo, E; Scotti, V; Alì, G; Mazzoni, F; Russo, A; Pignataro, D; Bulotta, A; Piovano, P; Sergi, C; Bettini, A; Genova, C; Pavan, A; Soto Parra, H; Ortega, C; Pozzessere, D; Vavalà, T; Chiari, R; Zannori, C; D'Aveni, A; Meoni, G; Giannarelli, D; Malapelle, U; Novello, S; Bria, E; Pasello, G
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04–2016
2025 Gelsomino, F; Boni, L; Tiseo, M; Ricciardi, S; Rocco, D; Cortinovis, D; Proietto, M; Cogoni, A; Pasello, G; Camerini, A; Sperandi, F; Colantonio, I; Metro, G; Mazzoni, F; Baldini, E; Veccia, A; Bennicelli, E; Cecilia Bettini, A; Tognetto, M; Ardizzoni, A
Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0)
2025 Crippa, V; Cordani, N; Villa, A; Malighetti, F; Villa, M; Sala, L; Aroldi, A; Piazza, R; Cortinovis, D; Mologni, L; Ramazzotti, D
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study
2025 Peters, S; Schulz, C; Reck, M; Prabhash, K; Kowalski, D; Szczesna, A; Han, B; Rittmeyer, A; Talbot, T; Vicente, D; Califano, R; Cortinovis, D; Le, A; Huang, D; Liu, G; Cappuzzo, F; Contreras, J; Palmero, R; Mak, M; Popat, S; Hu, Y; Morris, S; Srivastava, M; Kaul, M; Graupner, V; Gitlitz, B; Lee, S
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
2025 Cortellini, A; Brunetti, L; Di Fazio, G; Garbo, E; Pinato, D; Naidoo, J; Katz, A; Loza, M; Neal, J; Genova, C; Gettinger, S; Kim, S; Jayakrishnan, R; El Zarif, T; Russano, M; Pecci, F; Di Federico, A; Awad, M; Alessi, J; Montrone, M; Owen, D; Signorelli, D; Fidler, M; Li, M; Camerini, A; De Giglio, A; Young, L; Vincenzi, B; Metro, G; Passiglia, F; Yendamuri, S; Guida, A; Ghidini, M; Awosika, N; Napolitano, A; Fulgenzi, C; Grisanti, S; Grossi, F; D'Incecco, A; Josephides, E; Van Hemelrijck, M; Russo, A; Gelibter, A; Spinelli, G; Verrico, M; Tomasik, B; Giusti, R; Newsom-Davis, T; Bria, E; Sebastian, M; Rost, M; Forster, M; Mukherjee, U; Landi, L; Mazzoni, F; Aujayeb, A; Dupont, M; Curioni-Fontecedro, A; Chiari, R; Pantano, F; Morabito, A; Leonetti, A; Friedlaender, A; Addeo, A; Zoratto, F; De Tursi, M; Cantini, L; Roca, E; Mountzios, G; Della Gravara, L; Kalvapudi, S; Inno, A; Bironzo, P; Di Marco Barros, R; O'Reilly, D; Bell, J; Karapanagiotou, E; Monnet, I; Baena, J; Macerelli, M; Majem, M; Agustoni, F; Cortinovis, D; Tonini, G; Minuti, G; Bennati, C; Mezquita, L; Gorría, T; Servetto, A; Beninato, T; Lo Russo, G; Rogado, J; Moliner, L; Biello, F; Aboubakar Nana, F; Dingemans, A; Aerts, J; Ferrara, R; Torri, V; Hejleh, T; Takada, K; Naqash, A; Garassino, M; Peters, S; Wakelee, H; Nassar, A; Ricciuti, B
Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study
2025 Filippi, A; García Campelo, M; Paoli, J; Kowalski, D; Bennati, C; Borghetti, P; Cortinovis, D; Delmonte, A; Genova, C; Van Hulst, S; Mroz, R; Nawrocki, S; Toledano, I; Tonini, G; Agustoni, F; Wetherill, G; Zhu, Z; Perez, I; Foroutanpour, K; Georgoulia, N; Dziadziuszko, R
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer—final analysis from the phase II PACIFIC-6 trial
2025 Garassino, M; Khalifa, J; Reck, M; Chouaid, C; Bischoff, H; Reinmuth, N; Cove-Smith, L; Mansy, T; Cortinovis, D; Migliorino, M; Delmonte, A; Garcia Sánchez, J; Chara Velarde, L; Bernabe, R; Paz-Ares, L; Chander, P; Diaz Perez, I; Foroutanpour, K; Emeribe, U; Faivre-Finn, C
Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative Non-Small Cell Lung Cancer (NSCLC) – A meta-analysis based on reconstructed individual participant data
2025 Gemelli, M; Cortinovis, D; Carola, G; Moretti, L; Piazza, F; Calza, S; Ricotta, R; Grisanti, S; Rota, M
Immunotherapy in advanced non-small cell lung cancer: What to do for the ‘Invisible’ patients after IPSOS trial results?
2025 Gridelli, C; Attili, I; Bennati, C; Bironzo, P; Bria, E; Cortinovis, D; Soto Parra, H; De Marinis, F
Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer
2025 Crippa, V; Cordani, N; Villa, A; Malighetti, F; Villa, M; Sala, L; Aroldi, A; Piazza, R; Cortinovis, D; Mologni, L; Ramazzotti, D
Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study
2025 Liu, G; Solomon, B; Mazieres, J; Kim, D; Cortinovis, D; Inoue, T; Sharma, R; Thurm, H; Polli, A; Bauer, T
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy
2025 Leighl, N; Paz-Ares, L; Abreu, D; Hui, R; Baka, S; Bigot, F; Nishio, M; Smolin, A; Ahmed, S; Schoenfeld, A; Daher, S; Cortinovis, D; Di Noia, V; Linardou, H; Gainor, J; Dutcus, C; Okpara, C; Deng, X; Kush, D; Arunachalam, A; Song, A; Cho, B
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity
2025 Cortellini, A; Garbo, E; La Cava, G; Citarella, F; Santo, V; Brunetti, L; Pinato, D; Naidoo, J; Loza, M; Genova, C; Gettinger, S; Kim, S; Jayakrishnan, R; Zarif, T; Russano, M; Pecci, F; Di Federico, A; Montrone, M; Owen, D; Signorelli, D; Li, M; Camerini, A; Halmos, B; Vincenzi, B; Metro, G; Yendamuri, S; Grossi, F; Josephides, E; Tomasik, B; Giusti, R; Bria, E; Sebastian, M; Rost, M; Acker, F; Landi, L; Mazzoni, F; Morabito, A; Leonetti, A; Cantini, L; Mountzios, G; Kalvapudi, S; O'Reilly, D; Karapanagiotou, E; Monnet, I; Baena, J; Macerelli, M; Majem, M; Piedra, A; Cortinovis, D; Tonini, G; Minuti, G; Mezquita, L; Gorria, T; Beninato, T; Lo Russo, G; Prelaj, A; De Giglio, A; Biello, F; Nana, F; Dingemans, A; Aerts, J; Ferrara, R; Abu Hejleh, T; Takada, K; Naqash, A; Garassino, M; Wakelee, H; Nassar, A; Ricciuti, B; Soda, P; Caruso, C; Guarrasi, V
Next-generation radiomic sequencing in non-small cell lung cancer: an alternative model to predict mutations from [18F]FDG PET/CT
2025 Monaco, L; Crivellaro, C; De Bernardi, E; Bono, F; Casati, G; Seminati, D; Cortinovis, D; Elisei, F; L'Imperio, V; Landoni, C; Pagni, F; Turolla, E; Messa, C; Guerra, L
Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting
2025 De Marinis, F; Ardizzoni, A; Attili, I; Bonanno, L; Bria, E; Cortinovis, D; Margaritora, S; Mazzoni, F; Mercadante, E; Morabito, A; Petrella, F; Rea, F; Salvi, R; Solli, P; Spaggiari, L; Voltolini, L; Gridelli, C
Perioperative Chemo/Immunotherapies in Lung Cancer: A Critical Review on the Value of Perioperative Sequences
2025 Clementi, T; Colonese, F; Canova, S; Abbate, M; Sala, L; Petrella, F; Pagliari, G; Cortinovis, D
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis
2025 Malighetti, F; Villa, M; Villa, A; Pelucchi, S; Aroldi, A; Cortinovis, D; Canova, S; Capici, S; Cazzaniga, M; Mologni, L; Ramazzotti, D; Cordani, N
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study
2025 Gomez-Randulfe, I; Monaca, F; Cantale, O; Reale, M; Mrak, L; Zullo, L; Diaz, S; Bueno, M; Maridueña Moreno, M; Davis, C; Cox, S; Lee, D; Shah, R; Geldart, T; Baena, J; Benitez, J; Rosario Garcia Campelo, M; Remon, J; Planchard, D; Galetta, D; Tiseo, M; Cortinovis, D; Metro, G; Bria, E; Passiglia, F; Novello, S; Califano, R